Metropolis Healthcare introduces its novel stem cell transplant match testing tool

INDIA – Metropolis Healthcare has unveiled its novel diagnostic testing method to determine whether a patient has a suitable donor for Hematopoietic Stem Cell Transplant (HSCT) & solid organ transplantation, NextGen HLA Typing Test.

This novel test, powered by the complex molecular technology Next Generation Sequencing (NGS), will aid in the identification of a suitable donor for bone marrow, cord blood, or organ transplant.

In a press release, the company stated: “The NGS-based HLA Typing test eliminates the ambiguity in HLA Typing and provides the most accurate characterization of Alleles, making it one of the most advanced and reliable tests available in the market.”

This high-resolution molecular test is designed to support physicians in pointing out the HLA allelic genetic variants, which is clinically essential for matching donor and recipient for Hematopoietic & organ transplantation.

Metropolis’ NextGen HLA Typing Test analyses the Human Leukocyte Antigen (HLA) genes that a person has inherited from the parents to increase the chances of successful transplant outcomes.

The highly specialized testing method, widely regarded as the gold standard approach, can help doctors make better decisions for patients with hematological malignancies.

“HLA allelic information can be used to predict immune responses to various infectious diseases, genetic & autoimmune disorders,” Metropolis Healthcare said in a release.

The NextGen HLA Typing Test will help clinical experts in analyzing HLA, these genes encode proteins found on the outer surface of cells that are part of our body’s immune system.

Moreover, this breakthrough marks a step forward in the treatment of hematological malignancies, which result in leukemias, lymphomas, and myelomas.

Hematologic malignancies are cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system.

“The immune system uses HLAs to differentiate self-cells & non-self-cells. HLA system is activated when the body encounters something foreign, such as transplants, and attempts to reject it leading to graft failure,” informed Metropolis Healthcare.

The Indian multinational chain of diagnostic labs outlined that HLA genes determine a person’s unique HLA Type, which is critical for transplant success and higher survival rates.

Subsequently, Metropolis’ test will help to reduce the risk of immune complications such as graft rejection, Graft vs Host Disease (GVHD) and improve the survival rate of patients undergoing HSCT.

This ground-breaking development will further solidify Metropolis Healthcare’s position as a centre of excellence for all transplant-related diagnostic services in India and beyond.

Similarly, Metropolis Healthcare launched a next-generation sequencing platform that can rapidly identify drug resistance in TB patients and provide data on genotypic type levels of up to 18 TB antibiotics.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.